Contract Win

27 February 2025 - London, UK. IXICO plc (AIM: IXI, "IXICO" or "the Company") a global leader in neuroscience imaging, using its AI-driven platform to help advance therapy research in neurological disorders, today announces that it has signed a new commercial contract for a global Alzheimer's Disease (AD) imaging analysis with a leading biotechnology company, and secured an additional project in Huntington's Disease (HD) with an existing partner.

The combined value of the new contracts is more than £0.5 million, which will be recognised within a year, and increases the proportion of expected revenues for FY25 now contracted.

The positive commercial momentum continues IXICO's successful execution of its 'Innovate, Lead, Scale' strategy to drive expansion and growth. The nature of both agreements provides the potential for further revenues in the future.

New AD Contract

The AD contract is with a multinational biotechnology company, to provide imaging reads and data analysis using the dataset from the Global Alzheimer's Platform Foundation's groundbreaking Bio-Hermes-001 study, of which IXICO is a partner.

Additional HD Contract

The US headquartered client that contracted the Company to conduct a Phase 2 HD clinical trial, as announced on 10 December 2024, has subsequently deepened and extended its commercial partnership. Underlining IXICO's leading HD imaging platform status, a new project is being undertaken using the 'IXIQ.Ai' platform to reanalyse data from a previous Phase I clinical trial.

Bram Goorden, CEO of IXICO, commented: "The AD trial is a significant win for IXICO in that it complements the Company's strategy of expanding neuroimaging biomarker analysis for partners into the clinical diagnostics market. Both the AD contract win, and new HD project, reflect the continued recognition of IXICO as a global neuroimaging market leader with an unrivalled biomarker technology advantage."